Evaluating imaging response biomarkers in advanced prostate cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on the use of Lutetium-177 prostate-specific membrane antigen ([177Lu]Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). It aims to assess imaging response biomarkers to identify tumor progression early, potentially allowing for timely changes in treatment. The study utilizes the Response Evaluation Criteria in PSMA-imaging (RECIP) to evaluate therapeutic efficacy through PSMA-PET/CT imaging after initial treatment cycles. By monitoring these biomarkers, the study seeks to improve patient care and reduce unnecessary therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult aged 18 or older with proven adenocarcinoma of the prostate
* Diagnosis of progressive metastatic castration-resistant prostate cancer.
* Progression or intolerance on a novel anti-androgen therapy (i.e. abiraterone, enzalutamide, apalutamide or darolutamide)
* Prior therapy with at least one taxane-based chemotherapy during the course of prostate cancer or the patient is symptomatic and assessed as unfit for chemotherapy.
* ECOG Performance status 0 to 2

Exclusion Criteria:

* Patient opposed to the use of his data for clinical research.

Where it's running

• CHU Grenoble Alpes
  Grenoble, France Recruiting

Study contacts

• Study coordinator: Loïc DJAÏLEB, PU-PH
• Email: ldjaileb@chu-grenoble.fr
• Phone: 04 76 76 54 55

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted fluorescent dye OTL78 to guide prostate cancer surgery

  This study tests whether the PSMA-targeted fluorescent dye OTL78, used with near-infrared imaging, can help doctors better find and remove prostate cancer tissue during surgery in men with confirmed prostate cancer.

  Recruiting at 2 sites Phase 2/3 Indiana University · Carmel, Indiana and 1 other locations · NCT07725523

• Using PSMA PET with MRI to watch for prostate cancer returning after focal therapy

  We will try adding a PSMA PET scan to routine MRI follow-up to see if it finds prostate cancer coming back sooner in men who had focal (partial gland) therapy.

  Recruiting University of Chicago · Chicago, Illinois · NCT07115914

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

• Combining radiotherapy or surgery with intense hormone therapy for advanced prostate cancer

  This study is testing if combining surgery or radiation with strong hormone therapy can help men with newly diagnosed advanced prostate cancer feel better and live longer.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT06992232

• SRT for bone and lymph node metastases in advanced prostate cancer

  This trial tests whether treating multiple metastatic lesions with stereotactic radiotherapy can prolong pain control and prevent complications in men with advanced, treatment‑refractory prostate cancer.

  Recruiting Institut Cancerologie de l'Ouest · Saint-Herblain · NCT06978296

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.